Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord
blood transplant. The donor's immune system may recognize the your body (the host) as foreign
and attempt to 'reject' it. This process is known as graft-versus-host-disease. It is thought
that IL-2 may help control chronic GVHD by stopping the donor's immune system from
'rejecting' your body. In this research study, we are looking to see how IL-2 can be used in
combination with steroids to treat cGVHD.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
National Cancer Institute (NCI) Prometheus Laboratories